Medical Pharmacology Chapter 28: Physiology and Pharmacology: Adrenocorticosteroids / Adrenocortical Antagonists
Glucocorticoids (naturally occurring; cortisol -- hydrocortisone)
Major glucocorticoid: cortisol
Precursor: cholesterol
Site of adrenal cortisol synthesis:
Zona fasciculata
Zona reticularis
Cortisol release modulated by ACTH
Release rate of cortisol controlled by circadian rhythm affected by ACTH pulses
75% of cortisol bound to plasma proteins
Corticosteroid-binding globulin (CBG) --α2 globulin;
Cortisol also bound to serum albumin
Free cortisol plasma concentrations rise rapidly if CBG binding capacity is exceeded.
Factors that change plasma CBG concentration
↑pregnancy
↑estrogen administration (increased hepatic synthesis)
↑hyperthyroidism
↑hypothyroidism
↑protein deficiency
↑diminished synthetic capability (genetics)
Cortisol half-life: about 60-90 minutes
Factors that increase cortisol half-life
Stress
Hypothyroidism
Liver disease
Large dosage of hydrocortisone administration
20% converted to cortisone (by renal/other tissues with mineralocorticoid receptors) -- catalyzed by 11-hydroxysteroid dehydrogenase
Cortisol and cortisone inactivated in the liver by conversion (3-hydroxysteroid dehydrogenase catalyzed) to:
Tetrahydrocortisol
Tetrahydrocortisone
Other metabolites: cortol, cortolone
Some metabolites ultimately excreted in the urine as 11-oxy, 17-ketosteroids
Some metabolites undergo hepatic conjugation to form glucuronic acid or sulfate derivatives
Glucocorticoid action through glucocorticoid receptors
Member of receptor superfamily that includes:
Steroid receptors
Thyroid receptors
Other receptors (many with unknown function -- "orphan receptors"
Receptors bound to heat shock proteins (Hsp/hsp90)
Free glucocorticoid hormone enters the cell
Binds to the receptor, inducing a conformational change
Receptor dissociates from heat shock proteins
Hormone-receptor complex associate to form homodimers
Homodimers actively transported to the nucleus
Homodimers bind to glucocorticoid receptor elements (GREs) of target genes
Genomic effects: protein synthesized; Indirect mediation of some genomic effects by paracrine influences of hormone-regulated cytokines on nearby cells
Some physiological effects occur to rapidly to be accounted for by gene transcription/ protein synthesis:
Feedback suppression of pituitary ACTH (unknown mechanism)
Physiological effects of glucocorticoids
Major metabolic effects: due to direct cellular action
Some effects:secondary to homeostatic insulin and glucagon responses
Physiological responses modulated by glucocorticoids ("permissive" effects)
Catecholamine vascular/bronchial smooth muscle response:
Diminished in the absence of cortisol
Restored by physiological amounts of cortisol
Catecholamine-induced lipolytic adipocytes response:
Reduced in the absence of glucocorticoids (unknown mechanism)
Glucocorticoids: stimulate and are required for:
Gluconeogenesis (fasted state, diabetes);
Increasing hepatic and renal amino acid uptake
Increase gluconeogenic enzyme activity
Simulation of glycogen synthase
Increase glucose production from protein-- stimulating insulin release
Inhibit glucose uptake promoting increased lipolysis
Counteracted by enhanced insulin secretion which stimulates lipogenesis
Net effect: fat deposition
Glucocorticoid effects most prominent in the fasting state, through:
Stimulation: gluconeogenesis
Stimulation: amino acid release from muscle (catabolism)
Inhibition: peripheral glucose uptake
Stimulation: lipolysis
Promotion of catabolism:
Lymphoid tissue
Connective tissue
Muscle
Fat
Skin
High (supraphysiologic) glucocorticoid levels cause decreases in muscle mass and weakness
Reduced growth in children (not prevented by growth hormone)
Catabolic effects on bone:
Osteoporosis in Cushing's syndrome
Major limitation in long-term use
Anti-inflammatory/Immunosuppressive Effects
Reduction in inflammation
Leukocyte-mediated; reduced leukocyte infiltration
Glucocorticoid inhibition of interactions involving cell adhesion molecules (especially on endothelial cells)
Following glucocorticoid administration:
Neutrophils levels are increased, but a decrease is noted in lymphocytes (T and B cells, monocytes, eosinophils, basophils-- movement from vasculature to lymphoid tissue)
Glucocorticoids inhibit:
Leukocyte and tissue macrophage function
Reduced antigenic and mitogenic responsiveness
Macrophage effects:
Decreased interferon-gamma, interleukin 1, pyrogen, collagenase, elastase, tumor necrosis factor, plasminogen activator
Lymphocyte effects:
Decreased interleukin 2
Reduction of prostaglandin and leukotriene synthesis (resulting from phospholipase A2 activation)
Reduction of cyclooxygenase in inflammatory cells (reducing prostaglandin synthesis)
Of the two isoforms of cyclooxygenase (COX1 and COX-II), glucocorticoids inhibit COX-II gene expression.
Glucocorticoids decrease capillary permeability by:
Reducing kinin activity
Reducing bacterial endotoxin activity
Reducing basophils histamine release
Adrenal-insufficiency: EEG changes (slowing of alpha rhythms)
Increased levels: behavioral changes;
Decreased pituitary release of ACTH and beta-lipotropin
Decreased TSH and FSH secretion
Increased excess acid/pepsin production (large doses)
Increased fat absorption
In addition: effective vitamin D on calcium absorption
Increased platelet production, erythrocyte production
Without adequate cortisol: renal function -- impaired
Glucocorticoids important in tissue development (structure/functional changes in the lung)
Goldfien, A.,Adrenocorticosteroids and Adrenocortical Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 635-650.
Williams, G. H and Dluhy, R. G. , Diseases of the Adrenal Cortex, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 2035-2056
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals. |